Close Menu

NEW YORK ­– Tangen Biosciences has been awarded a $696,000 contract from the Biomedical Advanced Research and Development Authority to develop a point-of-care molecular diagnostic assay for the SARS-CoV-2 virus.

The test would run on Tangen's GeneSpark nucleic acid amplification system and would be sensitive enough for early detection of the virus from nasopharyngeal samples in about an hour. It would also be expected to garner a CLIA waiver for use in doctors' offices.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.